BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21386821)

  • 1. Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia.
    Ronen K; Negre O; Roth S; Colomb C; Malani N; Denaro M; Brady T; Fusil F; Gillet-Legrand B; Hehir K; Beuzard Y; Leboulch P; Down JD; Payen E; Bushman FD
    Mol Ther; 2011 Jul; 19(7):1273-86. PubMed ID: 21386821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.
    Cavazzana-Calvo M; Payen E; Negre O; Wang G; Hehir K; Fusil F; Down J; Denaro M; Brady T; Westerman K; Cavallesco R; Gillet-Legrand B; Caccavelli L; Sgarra R; Maouche-Chrétien L; Bernaudin F; Girot R; Dorazio R; Mulder GJ; Polack A; Bank A; Soulier J; Larghero J; Kabbara N; Dalle B; Gourmel B; Socie G; Chrétien S; Cartier N; Aubourg P; Fischer A; Cornetta K; Galacteros F; Beuzard Y; Gluckman E; Bushman F; Hacein-Bey-Abina S; Leboulch P
    Nature; 2010 Sep; 467(7313):318-22. PubMed ID: 20844535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.
    Malik P; Arumugam PI; Yee JK; Puthenveetil G
    Ann N Y Acad Sci; 2005; 1054():238-49. PubMed ID: 16339671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.
    Persons DA; Hargrove PW; Allay ER; Hanawa H; Nienhuis AW
    Blood; 2003 Mar; 101(6):2175-83. PubMed ID: 12411297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-thalassemia gene therapy.
    Li W; Xie S; Guo X; Gong X; Wang S; Lin D; Zhang J; Ren Z; Huang S; Zeng F; Zeng Y
    Haematologica; 2008 Mar; 93(3):356-62. PubMed ID: 18268280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia.
    Hanawa H; Hargrove PW; Kepes S; Srivastava DK; Nienhuis AW; Persons DA
    Blood; 2004 Oct; 104(8):2281-90. PubMed ID: 15198957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
    Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
    N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells.
    Imren S; Payen E; Westerman KA; Pawliuk R; Fabry ME; Eaves CJ; Cavilla B; Wadsworth LD; Beuzard Y; Bouhassira EE; Russell R; London IM; Nagel RL; Leboulch P; Humphries RK
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14380-5. PubMed ID: 12391330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy for beta-thalassemia.
    Malik P; Arumugam PI
    Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
    Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
    PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
    Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
    Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin gene therapy for β-thalassemia.
    Bank A
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1187-201. PubMed ID: 21075288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathies.
    Breda L; Ghiaccio V; Tanaka N; Jarocha D; Ikawa Y; Abdulmalik O; Dong A; Casu C; Raabe TD; Shan X; Danet-Desnoyers GA; Doto AM; Everett J; Bushman FD; Radaelli E; Assenmacher CA; Tarrant JC; Hoepp N; Kurita R; Nakamura Y; Guzikowski V; Smith-Whitley K; Kwiatkowski JL; Rivella S
    Mol Ther; 2021 Apr; 29(4):1625-1638. PubMed ID: 33515514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered U7 snRNA mediates sustained splicing correction in erythroid cells from β-thalassemia/HbE patients.
    Preedagasamzin S; Nualkaew T; Pongrujikorn T; Jinawath N; Kole R; Fucharoen S; Jearawiriyapaisarn N; Svasti S
    Biochem Biophys Res Commun; 2018 Apr; 499(1):86-92. PubMed ID: 29550480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients.
    Ouyang W; Dong G; Zhao W; Li J; Zhou Z; Yang G; Liu R; Li Y; Zhang Q; Du X; Sun H; Gu Y; Lai Y; Liu S; Liu C
    Hum Gene Ther; 2021 May; 32(9-10):481-494. PubMed ID: 33256481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia.
    Bank A; Dorazio R; Leboulch P
    Ann N Y Acad Sci; 2005; 1054():308-16. PubMed ID: 16339679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.
    Zhao HF; Abraham A; Kim YS; Wang YD; Pestina T; Zhan J; Humphries K; Nienhuis AW; Persons DA
    Mol Ther; 2017 Mar; 25(3):593-605. PubMed ID: 28190779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
    Persons DA; Allay ER; Sawai N; Hargrove PW; Brent TP; Hanawa H; Nienhuis AW; Sorrentino BP
    Blood; 2003 Jul; 102(2):506-13. PubMed ID: 12663444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preclinical approach for gene therapy of beta-thalassemia.
    Breda L; Kleinert DA; Casu C; Casula L; Cartegni L; Fibach E; Mancini I; Giardina PJ; Gambari R; Rivella S
    Ann N Y Acad Sci; 2010 Aug; 1202():134-40. PubMed ID: 20712784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
    Persons DA
    Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.